Novavax submits COVID vaccine candidate to TGA

By The Science Advisory Board staff writers

October 29, 2021 -- Novavax completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate in Australia.

The company said it has completed the submission of all modules required by the TGA for the regulatory evaluation of its COVID-19 vaccine. This includes preclinical, clinical, chemistry, manufacturing and controls data.

Novavax recently filed for conditional marketing authorization in the U.K. It expects to complete additional regulatory filings in Europe, Canada, New Zealand, and for the World Health Organization. The company expects to submit data to the U.S. Food and Drug Administration by the end of the year.

Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew...
Novavax touts COVID-19 vaccine results
Novavax is highlighting study results that demonstrate the efficacy of its COVID-19 vaccine, NVX-CoV2373, as well as a new COVID-19 vaccine it is developing...
Novavax posts positive preclinical results for flu/COVID-19 vaccine
Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine.
Novavax COVID vaccine effective vs. B.1.351 variant, inks deal with Gavi
Novavax announced results of a phase IIB trial of its COVID-19 candidate vaccine (NVX-CoV2373) published May 5 in the New England Journal of Medicine...
Novavax expands COVID-19 vaccine trial to include adolescents
Novavax has started a pediatric expansion of its phase III clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter